H pylori Eradication Moves From Ulcer Prevention to Cancer Prevention
Helicobacter pylori remains one of the most consequential chronic infections in gastrointestinal medicine. It infects more than 40% of people worldwide, with the highest burden concentrated in low- and middle-income countries, where access to screening and treatment is often uneven. Long after the initial acquisition, the organism can maintain a smoldering gastritis that quietly sets the stage for peptic ulcer disease, persistent dyspepsia, and eventually gastric adenocarcinoma.
The clinical logic behind eradication is straightforward, but the public health implications are much broader. Removing the bacterium interrupts the inflammatory cascade that drives mucosal injury and helps prevent the repeated cycles of ulceration and repair that can culminate in malignant transformation. In practical terms, treatment is not just symptom control. It is cancer prevention aimed at a known biologic driver.
A Recognized Carcinogen With a Large Global Footprint
The International Agency for Research on Cancer classifies H pylori as a Group 1 carcinogen, placing it among agents with clear causal links to human cancer. In this setting, gastric cancer is the central concern. The review identifies H pylori as the leading cause of infection-attributable cancer worldwide, with approximately 850,000 gastric cancer cases annually tied to the organism.
Those numbers matter because gastric cancer often emerges late, after years of silent progression. The bacterial burden is not distributed evenly across the globe, and the greatest disease load falls on regions where screening infrastructure is weakest. When prevalence is high and testing is fragmented, the result is a long tail of preventable ulcers, avoidable hospitalizations, and cancers that could have been intercepted earlier in the disease course.
Eradication Lowers Recurrence, Symptoms, and Cancer Incidence
Evidence assembled in the review supports eradication as a clinically meaningful intervention across several endpoints. Treatment reduces peptic ulcer recurrence, improves dyspepsia, and lowers gastric cancer incidence. Recent meta-analyses reported a pooled relative risk reduction of up to 44%, a magnitude that is difficult to ignore when the target is a malignancy with substantial mortality.
A single sentence captures the clinical stakes: removing H pylori changes downstream cancer risk.
The mechanism is biologically plausible. Chronic infection sustains inflammation, promotes epithelial injury, and creates a pro-carcinogenic environment in the gastric mucosa. Once that process is interrupted, the mucosal environment becomes less permissive to ulcer recurrence and less likely to progress toward dysplasia and cancer. For clinicians, the message is especially relevant in patients with a history of peptic ulcer disease or chronic dyspepsia, where eradication can alter the trajectory of future disease rather than simply relieve present symptoms.
Population-Based Programs Show What Eradication Can Do
The review points to population-level experience as the clearest demonstration of what systematic treatment can achieve. The Matsu Islands study is one such example, showing dramatic declines in H pylori prevalence, peptic ulceration, and gastric cancer incidence after eradication efforts were introduced.
These findings matter because they move the discussion beyond individual treatment decisions. When screening and treatment are applied broadly in high-prevalence settings, the impact extends from the endoscopy suite to cancer incidence curves at the community level. The benefit is especially compelling in regions where gastric cancer has remained entrenched despite improvements in general medical care, suggesting that pathogen-directed prevention can outperform reactive diagnosis alone.
The experience from such programs also illustrates why timing and coverage are critical. Treating infection after substantial premalignant change has already occurred may blunt the achievable benefit, whereas earlier detection and eradication can prevent the inflammatory sequence before irreversible damage accumulates.
Guidelines Are Shifting Toward Universal Eradication of Confirmed Infection
International guidance has moved decisively in favor of broader treatment. The Maastricht VI/Florence consensus and the 2025 Taipei Global Consensus now recommend universal eradication of confirmed infections. They also support population-level or family-based screening in high-risk regions, reflecting a growing consensus that case-by-case management alone is insufficient where prevalence and cancer risk remain high.
This shift is clinically important because it reframes H pylori as a public health target rather than a narrow infectious disease diagnosis. Family-based screening may be especially useful where household clustering contributes to transmission, while population-level strategies can identify infected individuals before complications emerge. In both models, the goal is the same: find infection early, confirm it accurately, and clear it before prolonged mucosal injury accumulates.
Antibiotic Resistance Complicates Care but Does Not Cancel the Strategy
Antibiotic resistance remains a real constraint on eradication programs. Resistance can erode treatment success if regimens are chosen blindly or if stewardship is weak. The review does not frame resistance as a reason to abandon treatment; instead, it treats resistance as a management problem that can be addressed through appropriate antibiotic stewardship.
That approach is consistent with current practice. Effective eradication depends on selecting regimens with attention to local resistance patterns, prior antibiotic exposure, and treatment adherence. The more the field relies on empiric, poorly adapted regimens, the more likely treatment failure becomes. As a result, implementation has to be paired with surveillance and rational antibiotic use, particularly in regions where macrolide or other resistance patterns are already well established.
European Implementation Still Needs Stronger Data
Despite the strength of the biologic rationale and the encouraging results from population-based programs, large-scale implementation in Europe remains incomplete. The review points to ongoing European pilot studies, including the TOGAS initiative, designed to inform how gastric cancer screening can be built into practice.
A direct policy question remains: how should health systems balance cost, access, and test-and-treat infrastructure against the long-term benefit of preventing cancer? The review argues that population-based H pylori screen-and-treat strategies are cost-effective and evidence-based, but optimal implementation still depends on local epidemiology, healthcare capacity, and the feasibility of sustained screening.
Large-scale European studies are still needed to clarify which populations benefit most, how early programs should begin, and how best to integrate eradication into existing cancer prevention pathways. The clinical case is already strong; the next challenge is operational. Health systems must decide whether they are prepared to treat a common infection as a cancer prevention priority rather than a sporadic gastrointestinal finding.